Klox Technologies announces positive top-line results from a pivotal study of Phovia(TM) for the management of Canine Deep Pyoderma
DUBLIN, Ireland, July 02, 2018 (GLOBE NEWSWIRE) -- Klox Technologies Limited, a subsidiary of Klox Technologies Inc. ('KTI') has announced they have completed a pivotal study of Phovia for the management of Canine Deep Pyoderma. The 80-patient study met all endpoints and demonstrated that Phovia significantly reduces time to clinical resolution while reducing the duration of antibiotic use.
Phovia is a first-in-class, topical fluorescence biomodulating product, using proprietary technology, to engage inherent biological systems.
This prospective, randomized, controlled, blinded study compared the current standard of care (systemic antibiotic therapy) versus the standard of care plus Phovia twice weekly, until clinical resolution was achieved.
Phovia demonstrated efficacy for the primary endpoint, with the proportion of patients reaching clinical resolution at six (6) weeks being 26.5% for the control group and 84.6% for the Phovia treated group (p<0.001). The statistically significant differences between the two (2) groups were obtained as soon as week three (3). For the secondary endpoints, the Phovia treated group showed a statistically significant reduction of clinical scores, and an improvement in neutrophil engulfing bacteria scores. An exploratory endpoint demonstrated that the median time to clinical resolution for the control group was 12.7 weeks while the Phovia treated group was 4.0 weeks; a significant reduction in treatment times. No product related adverse events were recorded.
Prof. Andrea Spaterna from the University of Camerino, Italy, and principal investigator of the Phovia study, stated that, "Reducing the treatment time of deep pyodermas to this extent is tremendous news for veterinarians, patients and owners alike. A critical part of the results includes reducing the duration of systemic antibiotic use, as it is becoming abundantly clear in the international community that long-term antibiotic use has a high risk factor for the development of antibiotic resistant bacteria."
Investigators strongly believe that a product like Phovia is ready for the veterinary market, as veterinarians and pet owners are more reluctant to treat patients with long-term antibiotics. "I am finding most pet owners are really open to innovative therapies like Phovia, and having the patients come into the clinic for treatment allows for better monitoring of deep pyodermas", concluded Prof. Spaterna.
Klox is advancing discussions with potential partners to bring Phovia, and its pipeline products to market. Partnerships are expected to be announced later this year, and Phovia is anticipated to be commercially available in Europe during H1 2019.
Phovia is a first-in-class, topical fluorescence biomodulating product, using proprietary technology, to engage inherent biological systems. It is based on Klox's patented Fluorescence Biomodulation technology platform, which is a non-invasive, non-thermal technology targeted to improve the management of serious skin/soft tissue disorders for companion animals and horses. It is intended to create an environment that promotes accelerated healing of pyoderma lesions in dogs and promotes wound healing in dogs, cats and horses.
About Canine Deep Pyoderma
Canine deep pyoderma (CDP) is a difficult to treat skin disease in small animals1 characterized by dissemination of bacteria into the deep dermis and/or bacterial infection of the panniculus. The causative organism is Staphylococcus pseudintermedius(formerly S. intermedius) in the vast majority of cases. Bacteria in lesions of deep pyoderma are often located in the center of fibrotic or inflammatory foci, associated with chronic diseases and scarring. Recurrence of the disease is frequent, which requires long-term systemic antibiotic use, and an additional one to two (2) weeks of extended antibiotic use post clinical resolution to ensure complete microbiological remission2,3.
About Klox Technologies
Klox Technologies Inc. is a private biomedical technology innovator, advancing the development and commercialization of its flagship fluorescence generating technology for specific skin/soft tissue conditions and diseases. With franchises in wound care, dermatology, veterinary and oral health, Klox is well positioned to capitalize on significant market opportunities. For more information please visit www.kloxtechnologies.com
Klox Technologies Limited
Dr. Ricardo Garvao, Head of Animal Health
+353 (0) 1 7006216
- Lund EM, Armstrong PJ, Kirk CA et al. Health status and population characteristics of dogs and cats examined at private veterinary practices in the United States. Journal of the American Animal Hospital Association 1999; 214: 1336-41.
- Scott DW, Miller WH Jr, Griffin CE. Muller and Kirk's Small Animal Dermatology, 6th edn, ed. Philadelphia: W.B. Saunders, 2001; 453-7.
- Spaterna A. Dermatosi a carattere pustoloso e/o foruncoloso. In: Spaterna A. Dermatologia del cane, dal segno clinico alla diagnosi e terapia, Point Vet. Italie Ed., Milano, 2008; 139-170.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Klox Technologies, Inc. via Globenewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg saker fra GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra GlobeNewswire
Avis Budget Group Wins Multiple Awards in the Middle East26.4.2019 12:43:00 CEST | Pressemelding
LONDON, April 26, 2019 (GLOBE NEWSWIRE) -- Avis Budget Group has been awarded multiple accolades at the 2019 World Travel Awards, for its car rental brands Avis and Budget, across the Middle East, it was announced at an awards ceremony in Abu Dhabi last night. The 26th annual World Travel Awards is globally recognized as a highly prestigious honours programme in global travel and tourism. The awards are voted for by travel and tourism professionals and consumers worldwide, and this honour recognises the brands’ commitment to excellence, with an ultimate industry accolade. The awards won by these licensee markets within Avis Budget Group include: Middle East's Leading Business Car Rental Company 2019: Avis Bahrain's Leading Car Rental Company 2019: Avis Iraq's Leading Car Rental Company 2019: Avis Kuwait's Leading Car Rental Company 2019: Avis Lebanon's Leading Car Rental Company 2019: Avis Oman's Leading Car Rental Company 2019: Avis United Arab Emirates’ Leading Car Rental Company 201
Mohawk Industries Reports Q1 Results25.4.2019 22:15:00 CEST | Pressemelding
CALHOUN, Ga., April 25, 2019 (GLOBE NEWSWIRE) -- Mohawk Industries, Inc. (NYSE: MHK) today announced 2019 first quarter net earnings of $122 million and diluted earnings per share (EPS) of $1.67. Adjusted net earnings were $154 million, and EPS was $2.13, excluding restructuring, acquisition and other charges. Net sales for the first quarter of 2019 were $2.44 billion, up 1% in the quarter and 6% on a constant currency and days basis. For the first quarter of 2018, net sales were $2.41 billion, net earnings were $209 million and EPS was $2.78, adjusted net earnings were $225 million, and EPS was $3.01, excluding restructuring, acquisition and other charges. Commenting on Mohawk Industries’ first quarter performance, Jeffrey S. Lorberbaum, Chairman and CEO, stated, “In the first quarter, we delivered results in-line with the high end of our expectations despite economies weakening in most regions and a stronger U.S. dollar, reducing our translated results. While U.S. housing markets beg
Oxford Immunotec Schedules First Quarter 2019 Earnings Release and Conference Call for May 9, 201925.4.2019 22:05:00 CEST | Pressemelding
OXFORD, United Kingdom and MARLBOROUGH, Mass., April 25, 2019 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the "Company"), a global, high-growth diagnostics company, today announced that it plans to release first quarter 2019 financial results before the open of the market on Thursday, May 9, 2019. Dr. Peter Wrighton-Smith, Chief Executive Officer, and Matt McLaughlin, Chief Financial Officer, will host a conference call to review the Company's financial results at 8:00 a.m. Eastern Time the same day. The call will be concurrently webcast. To listen to the conference call on your telephone, please dial (855) 363-5047 for United States callers or +1 (484) 365-2897 for international callers and reference confirmation code 6687808, approximately ten minutes prior to start time. To access the live audio webcast or subsequent archived recording, visit the Investor Relations section of Oxford Immunotec's website at www.oxfordimmunotec.com. The replay will be available on th
Novavax to Host Conference Call to Discuss First Quarter Financial Results on May 2, 201925.4.2019 22:05:00 CEST | Pressemelding
GAITHERSBURG, Md., April 25, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX) today announced it will report its first quarter 2019 financial and operating results following the close of U.S. financial markets on Thursday, May 2, 2019. Conference call details are as follows: Date: May 2, 2019 Time: 4:30 p.m. U.S. Eastern Time (ET) Dial-in number: (877) 212-6076 (Domestic) or (707) 287-9331 (International) Passcode: 5394082 Webcast: www.novavax.com, “Investors”/ “Events” Conference call and webcast replay: Dates: Starting at 7:30 p.m. ET, May 2, 2019 until 7:30 p.m. ET May 9, 2019 Dial-in number: (855) 859-2056 (Domestic) or (404) 537-3406 (International) Passcode: 5394082 Webcast: www.novavax.com, “Investors”/ “Events”, until August 2, 2019 About Novavax Novavax, Inc. (Nasdaq:NVAX) is a late-stage biotechnology company that drives improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. Its tw
BGRS Acquired by Relo Group, Inc.25.4.2019 17:55:00 CEST | Pressemelding
CHICAGO and TOKYO, April 25, 2019 (GLOBE NEWSWIRE) -- Relo Group, Inc. (“Relo Group”) and BGRS (“BGRS” or the “Company”) announced today that they have entered into a definitive agreement under which an affiliate of Relo Group will acquire BGRS, a leading global talent mobility management firm from Brookfield Business Partners. Leading the global mobility industry with innovative outsourcing and fully integrated solutions, BGRS provides a full spectrum of talent mobility and advisory services to Global Fortune 500 companies. Supported by a team of over 1,300 globally, BGRS manages over 60,000 employee relocations annually with locations throughout Asia, the Americas and EMEA. BGRS Chief Executive Officer, Traci Morris, and the management team will remain in place and work with Relo Group to advance the Company into its next phase. “BGRS has developed into a world class talent mobility management firm by always putting the interests of our clients first, constantly innovating and search
Ascom adds ‘talk before walk’ wireless speech function to new release of Ascom teleCARE IP25.4.2019 14:00:00 CEST | Pressemelding
New feature helps reduce caregivers’ walking time; enables more streamlined workflows in elderly care facilities BAAR, Switzerland, April 25, 2019 (GLOBE NEWSWIRE) -- Ascom (SWX:ASCN.SW), a global solutions provider focused on healthcare ICT and mobile workflow solutions, has added wireless speech functionality to its latest version of the Ascom teleCARE IP emergency call system. The new feature promises to help reduce the time spent by staff walking to investigate calls from residents in continuing and elderly care facilities. Ascom teleCARE IP has always had hardwired speech functionality. But by making it wireless, residents can simply use their normal mobile phones to communicate directly with caregivers via Ascom teleCARE IP. Caregivers can communicate with residents while on the go, and can deal with residents’ calls before walking to investigate. The newly released (Ascom teleCARE IP 12) is available globally. The latest version also features several technical enhancements inclu